Biophan CEO Michael Weiner to Speak at the 2006 Milken Institute Global Conference on Alternative Financing Panel
The panel will explore various ways to use alternative financing vehicles to fund medical innovation. Nir Kossovsky, Founder, President and CEO, Technology Option Capital LLC, will be the moderator of the panel. Other panelists joining Mr. Weiner include Roy Doumani, Acting COO, California NanoSystems Institute; James Heywood, CEO and d'Arbeloff Founding Director, ALS Therapy Development Foundation; and Geoffrey Parker, Partner, Investment Banking, Goldman Sachs.
Mr. Weiner said, "Specialty medical technology companies such as Biophan are playing increasingly important roles in healthcare industry innovation. We are bringing to market solutions that traditional venture capital sources may not fund, such as our stent and pacemaker technologies. There are many other promising innovations that fall outside of the sweet spot of venture capital sources, but can be superb opportunities for alternative financing vehicles, such as the public market financing sources we at Biophan are successfully utilizing. I am delighted to be speaking at the Global Conference 2006 and look forward to participating on the panel and sharing the Biophan experience in bringing important new innovations to the healthcare field. The Milken Conference panel is exploring how foundations and healthcare researchers can interact with industry organizations and alternative funding vehicles. We are very excited to have been asked to participate."
About The Milken Institute
The Milken Institute is a nonprofit, independent economic think tank whose mission is to improve the lives and economic conditions of diverse populations around the world by helping business and public policy leaders identify and implement innovative ideas for creating broad-based prosperity. It is based in Santa Monica, CA. www.milkeninstitute.org
Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications, plus international applications. This total includes 50 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 98 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.